Trial Profile

A study assessing FCN-207 for gout

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FCN-207 (Primary)
Indications Gout
Focus Adverse reactions

Most Recent Events

17 Mar 2020 New trial record
08 Mar 2020 According to a Fosun pharma media release, the company has received application acceptance notification (acceptance nos. CXHL2000046 (Guo) and CXHL2000047 (Guo)) for clinical trial registration from the National Medical Products Administration (NMPA) for its FCN-207 tablet, a new drug for the treatment of hyperuricemia or gout.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com